anmelden
OMX Copenhagen 20
1.539,57
PKT
+38,10
PKT
+2,54
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Copenhagen 20-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 03.02.22 | Novo Nordisk Neutral | Credit Suisse Group | |
| 02.02.22 | Novo Nordisk Outperform | Bernstein Research | |
| 02.02.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 02.02.22 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 02.02.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 01.02.22 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 31.01.22 | Novo Nordisk Overweight | Barclays Capital | |
| 26.01.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 26.01.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 25.01.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 24.01.22 | Novo Nordisk Outperform | Bernstein Research | |
| 18.01.22 | A.P. Moeller - Maersk A-S (B) Buy | Deutsche Bank AG | |
| 06.01.22 | Novo Nordisk Hold | Deutsche Bank AG | |
| 06.01.22 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 04.01.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 04.01.22 | Novo Nordisk Outperform | Bernstein Research | |
| 21.12.21 | Novo Nordisk Hold | Kepler Cheuvreux | |
| 21.12.21 | Novo Nordisk Overweight | Barclays Capital | |
| 20.12.21 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 07.12.21 | Novo Nordisk Buy | Deutsche Bank AG | |
| 07.12.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 29.11.21 | Novo Nordisk Buy | Deutsche Bank AG | |
| 29.11.21 | A.P. Moeller - Maersk A-S (B) Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 26.11.21 | Novo Nordisk Neutral | UBS AG | |
| 26.11.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 26.11.21 | Novo Nordisk Outperform | Bernstein Research | |
| 22.11.21 | Novo Nordisk Overweight | Barclays Capital | |
| 19.11.21 | Novo Nordisk Neutral | UBS AG | |
| 18.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 15.11.21 | A.P. Moeller - Maersk A-S (B) Neutral | JP Morgan Chase & Co. | |
| 11.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.11.21 | Novo Nordisk Neutral | Credit Suisse Group | |
| 04.11.21 | Novo Nordisk Overweight | Barclays Capital | |
| 04.11.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 03.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 03.11.21 | Novo Nordisk Outperform | Bernstein Research | |
| 03.11.21 | Novo Nordisk Neutral | UBS AG | |
| 03.11.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 01.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 29.10.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. |